Nielsen L L, Gurnani M, Porter G, Trexler S, Emerson D, Tyler R D
Department of Tumor Biology, Schering-Plough Research Institute, Kenilworth, NJ 07033.
In Vivo. 1994 May-Jun;8(3):295-302.
A novel cell line (WR21) was derived from a salivary tumor in a male wap-ras transgenic mouse. Salivary tumors in wap-ras transgenic mice are extremely aggressive and express high levels of oncogenic ras protein from the activated, human Ha-ras transgene. WR21 cells also expressed high levels of oncogenic ras protein in vitro and in vivo. They gave rise to aggressive, highly anaplastic solid tumors when injected subcutaneously into athymic nude mice and approximately 90% of the mice had lung metastases by the fifth week of tumor growth. WR21 tumors were inhibited by cyclophosphamide, 5-fluorouracil, adriamycin, mitomycin C and actinomycin D, but not methotrexate. Our results suggest that the WR21/nude mice model will be useful for testing the efficacy of drug therapies against ras-mediated neoplasias.
一种新的细胞系(WR21)源自一只雄性wap-ras转基因小鼠的唾液腺肿瘤。wap-ras转基因小鼠的唾液腺肿瘤极具侵袭性,并且从激活的人Ha-ras转基因中表达高水平的致癌性ras蛋白。WR21细胞在体外和体内也表达高水平的致癌性ras蛋白。当皮下注射到无胸腺裸鼠体内时,它们会形成侵袭性强、高度间变的实体瘤,并且在肿瘤生长的第五周时,约90%的小鼠发生肺转移。WR21肿瘤受到环磷酰胺、5-氟尿嘧啶、阿霉素、丝裂霉素C和放线菌素D的抑制,但不受甲氨蝶呤的抑制。我们的结果表明,WR21/裸鼠模型将有助于测试针对ras介导的肿瘤形成的药物治疗效果。